Global Personal Care Contract Manufacturing Market to Cross USD 40 Billion by 2032
LAS VEGAS, Aug. 19, 2025 /PRNewswire/ — DelveInsight's Personal Care Contract Manufacturing Market Insights report provides the current and forecast market analysis, individual leading personal care contract manufacturing companies' market shares, challenges, personal care contract manufacturing market drivers, barriers, trends, and key market personal care contract manufacturing companies in the market.
Key Takeaways from the Personal Care Contract Manufacturing Market Report
As per DelveInsight estimates, North America is anticipated to dominate the global personal care contract manufacturing market during the forecast period.
In the application segment of the personal care contract manufacturing market, the skin care category accounted for the largest market share in 2024.
Notable personal care contract manufacturing companies such as Albea Group, McBride, Colep Consumer Products, PLZ Corp., Voyant Beauty, Formula Corp., INTERCOS S.P.A., H.S.A. Hair Styling Applications S.p.A., Clarion Cosmetics, COMECER S.p.A., Novo Nordisk A/S, Siegfried Holding AG, Aenova Group, SED Pharma, 3P innovation Ltd., FUJIFILM Holdings Corporation, BRAM-COR SPA, and groninger & Co. GmbH, Danaher Corporation, Syntegon Technology GmbH, and several others, are currently operating in the personal care contract manufacturing market.
In October 2024, Evonik and Kolmar Cosmetics (Wuxi) Co., Ltd. officially entered into a strategic partnership agreement in Wuxi, China. This collaboration is focused on driving innovation in raw materials by developing sustainable ingredients, advanced sun care solutions, color cosmetics, and high-performance active ingredients. The partnership also emphasizes novel formulation research, aiming to enhance product development capabilities and support the growing demand for innovative and eco-friendly personal care solutions.
To read more about the latest highlights related to the personal care contract manufacturing market, get a snapshot of the key highlights entailed in the Global Personal Care Contract Manufacturing Market Report
Personal Care Contract Manufacturing Overview
Personal care contract manufacturing refers to outsourcing the production of personal care and cosmetic products to specialized third-party manufacturers. This approach allows brand owners to focus on core activities such as marketing, distribution, and innovation while leveraging the expertise, infrastructure, and regulatory compliance capabilities of contract manufacturers. The industry covers a wide range of products, including skincare, haircare, oral care, and cosmetics, offering services like formulation development, product testing, packaging, and labeling. With increasing consumer demand for high-quality, innovative, and safe products, contract manufacturers are investing in advanced technologies, sustainable practices, and flexible production capacities to cater to both emerging and established brands.
Personal Care Contract Manufacturing Market Insights
In 2024, North America dominated the personal care contract manufacturing market, driven by increasing consumer expenditure on personal care and cosmetic products, higher disposable incomes, and rising demand for innovative, premium-quality solutions. The region is also experiencing a notable uptick in collaborations and partnerships among major industry players, aimed at creating advanced and diverse product portfolios.
Additionally, companies are expanding their service offerings to align with the evolving needs of brands. For example, in February 2024, Aptar Beauty introduced Turnkey Solutions by Aptar™, a comprehensive service integrating advanced formulations, in-house laboratory capabilities, and a network of expert partners with Aptar's established expertise in filling and distribution, enabling end-to-end support for personal care product development.
As a result, the combined effect of surging demand for personal care products and increased consumer spending on cosmetics is anticipated to substantially drive market growth in North America between 2025 and 2032.
To know more about why North America is leading the market growth in the personal care contract manufacturing market, get a snapshot of the Personal Care Contract Manufacturing Market Outlook
Personal Care Contract Manufacturing Market Dynamics
The personal care contract manufacturing market is experiencing robust growth, driven by rising consumer demand for high-quality, innovative, and customized personal care products. As brand owners increasingly focus on marketing, brand building, and customer engagement, many are outsourcing formulation, production, and packaging to specialized contract manufacturers. This shift allows companies to reduce capital expenditure on manufacturing facilities and leverage the expertise, technology, and scalability of third-party partners. Growing consumer expectations for product variety, sustainable formulations, and shorter launch cycles are further fueling the reliance on contract manufacturing in this sector.
One of the key demand drivers is the growing preference for natural, organic, and clean-label products. With heightened awareness of ingredient safety and environmental sustainability, consumers are pushing brands to reformulate products with eco-friendly, cruelty-free, and non-toxic ingredients. Contract manufacturers are responding by investing in R&D capabilities, green chemistry processes, and sustainable packaging solutions to meet regulatory requirements and consumer expectations. Additionally, the rising purchasing power in emerging economies and the premiumization trend in mature markets are creating new growth opportunities for both global and regional contract manufacturing players.
From a supply-side perspective, the market is shaped by technological advancements and operational efficiencies. Automation, advanced formulation technologies, and flexible manufacturing systems enable contract manufacturers to cater to both small-batch niche products and large-scale mass-market items. Strategic partnerships between brands and manufacturers are increasingly common, enabling faster time-to-market and shared innovation. However, the competitive landscape is intense, with manufacturers differentiating themselves through quality certifications, compliance with Good Manufacturing Practices (GMP), and the ability to offer end-to-end services, from product ideation to distribution-ready packaging.
Challenges in the market include stringent regulatory environments and fluctuating raw material costs. Personal care products often require adherence to strict quality and safety regulations, which vary across regions and product categories. This necessitates significant investment in compliance infrastructure, documentation, and testing capabilities. Volatility in the prices of natural oils, botanical extracts, and other raw materials can also affect production costs and profit margins. Furthermore, the rise of private-label brands has intensified competition, compelling contract manufacturers to continuously innovate and maintain cost efficiencies.
Looking ahead, the personal care contract manufacturing market is poised for sustained expansion, with digitalization, customization, and sustainability as key strategic pillars. E-commerce growth is driving demand for smaller, more diverse product lines, while the rise of direct-to-consumer (DTC) beauty brands creates fresh opportunities for agile manufacturing models. Players that can offer flexible, compliant, and sustainable solutions while fostering collaborative partnerships with brand owners are likely to gain a competitive edge in this dynamic market landscape.
Get a sneak peek at the personal care contract manufacturing market dynamics @ Personal Care Contract Manufacturing Market Dynamics Analysis
Report Metrics
Details
Coverage
Global
Study Period
2022–2032
Personal Care Contract Manufacturing Market CAGR
~8%
Personal Care Contract Manufacturing Market Size by 2032
~USD 42 Billion
Key Personal Care Contract Manufacturing Companies
Albea Group, McBride, Colep Consumer Products, PLZ Corp., Voyant Beauty, Formula Corp., INTERCOS S.P.A., H.S.A. Hair Styling Applications S.p.A., Clarion Cosmetics, COMECER S.p.A., Novo Nordisk A/S, Siegfried Holding AG, Aenova Group, SED Pharma, 3P innovation Ltd., FUJIFILM Holdings Corporation, BRAM-COR SPA, and groninger & Co. GmbH, Danaher Corporation, Syntegon Technology GmbH, and others
Personal Care Contract Manufacturing Market Assessment
Personal Care Contract Manufacturing Market Segmentation
Personal Care Contract Manufacturing Market Segmentation By Offering: Products (Tubes, Jars & Bottles, Spray, and Others) and Services
Personal Care Contract Manufacturing Market Segmentation By Formulation: Liquids, Powders, Aerosols, Creams, and Others
Personal Care Contract Manufacturing Market Segmentation By Application: Skin Care, Hair Care, and Others
Personal Care Contract Manufacturing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
Which MedTech key players in the personal care contract manufacturing market are set to emerge as the trendsetter explore @ Personal Care Contract Manufacturing Companies
Table of Contents
1
Personal Care Contract Manufacturing Market Report Introduction
2
Personal Care Contract Manufacturing Market Executive Summary
3
Competitive Landscape
4
Regulatory Analysis
5
Personal Care Contract Manufacturing Market Key Factors Analysis
6
Personal Care Contract Manufacturing Market Porter's Five Forces Analysis
7
Personal Care Contract Manufacturing Market Layout
8
Personal Care Contract Manufacturing Market Company and Product Profiles
9
KOL Views
10
Project Approach
11
About DelveInsight
12
Disclaimer & Contact Us
Interested in knowing the personal care contract manufacturing market by 2032? Click to get a snapshot of the Personal Care Contract Manufacturing Market Trends
Related Reports
Contract Development Manufacturing Organization Market
Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, among others.
Biopharmaceuticals Contract Manufacturing Market
Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.
Biologics Drug Substance Fill and Finish Manufacturing Market
Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, among others.
Biologics Drug Substance Manufacturing Market
Biologics Drug Substance Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance manufacturing companies, including Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A/S, Siegfried Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD., FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact UsShruti Thakur info@delveinsight.com +14699457679https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-personal-care-contract-manufacturing-market-to-cross-usd-40-billion-by-2032–delveinsight-302533171.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Argus launches gasoline price for Middle East
Investments in refining infrastructure and rising regional production have led to calls for a dedicated Middle East gasoline benchmark DUBAI, UAE, Aug. 20, 2025 /PRNewswire/ — Global energy and commodity price reporting agency Argus has launched a new 'MEBOB' daily assessment, directly reflecting the price of gasoline produced and loaded in the Middle East. Refining capacity in the Mideast Gulf has risen to over 10.5mn b/d as of last year. Underlying demand has also grown in and around the region. The production of gasoline has increased in the past seven years from about 1.7mn b/d to close to 2.4mn b/d and gasoline exports have more than doubled to 654,000 b/d from 270,000 b/d, including intra-regional flows. Historically, gasoline made in the Middle East has been priced using a Singapore market value adjusted for freight. But increasingly this approach does not reflect local supply and demand conditions. And recent volatility in tanker freight rates, caused by disruptions on key routes, has added further distortion. As a result, the two markets are increasingly independent of each other. The Argus MEBOB assessment is an outright price based on local activity during the UAE trading day and is not derived from the Singapore market. Argus is facilitating the conduct of trade with its Argus Open Markets platform — a real-time electronic price discovery tool. Argus Media chairman and chief executive Adrian Binks said: 'The Middle East needs its own independently assessed gasoline price representing local market fundamentals and not those of a faraway and increasingly disconnected region. The MEBOB price offers important transparency, will enable better risk management and planning, and completes a global market picture.' The new MEBOB price has been developed in close consultation with local producing, consuming and trading companies. It represents the price of oxygenated 92 Ron gasoline, which is widely available in the region, as loaded in Fujairah, Jebel Ali or Sohar. Market information about other qualities of gasoline and loading ports can also be considered on an adjusted basis to create the price. Argus also publishes octane and crack spreads to further increase transparency in the region. The MEBOB price complements the Argus Eurobob gasoline price, which is the industry-wide benchmark for Europe. Derivatives settled on Argus Eurobob are used to manage price exposure across Europe and the global gasoline complex. Argus contact information London: Seana Lanigan+44 20 7780 4200Email Seana Houston: Matt Oatway+1 713 968 0000Email Matt Singapore: Tomoko Hashimoto+65 6496 9960Email Tomoko About Argus Media Argus is the leading independent provider of market intelligence to the global energy and commodity markets. We offer essential price assessments, news, analytics, consulting services, data science tools and industry conferences to illuminate complex and opaque commodity markets. Headquartered in London with over 1,500 staff, Argus is an independent media organisation with 30 offices in the world's principal commodity trading hubs. Companies, trading firms and governments in 160 countries around the world trust Argus data to make decisions, analyse situations, manage risk, facilitate trading and for long-term planning. Argus prices are used as trusted benchmarks around the world for pricing transportation, commodities and energy. Founded in 1970, Argus remains a privately held UK-registered company owned by employee shareholders and global growth equity firm General Atlantic. Trademark notices ARGUS, the ARGUS logo, ARGUS MEDIA, ARGUS DIRECT, ARGUS OPEN MARKETS, AOM, FMB, DEWITT, JIM JORDAN & ASSOCIATES, JJ&A, FUNDALYTICS, METAL-PAGES, INTEGER, Argus publication titles and Argus index names are trademarks of Argus Media Limited.
Malaysian Reserve
7 hours ago
- Malaysian Reserve
BDIC HK LTD Launches StableCover Pro to Provide Risk Coverage for Institutional Stablecoin Holdings
HONG KONG, Aug. 20, 2025 /PRNewswire/ — BDIC HK LTD (a division of Blockchain Deposit Insurance Corporation) released news today and had further comments by Co-Founder and PanAsia MD, as well as the Founder / CEO, as the crypto insurance provider laid out its tactical plans around the emergence of stablecoins in the digital economy. The company representatives see the timing of the complimentary product launch of StableCover Pro (alongside its standard digital currency insurance solution) for the corporate clients to be perfect. StableCover Pro will be providing comprehensive risk coverage for digital currency stablecoin assets that meet strict regulatory standard: Full backing by U.S. cash or Treasury bills, guaranteed 1:1 redemption rights, consistent peg maintenance, and independent reserve attestations. Paul Kohli, the MD of PanAsia and Co-Founder, comments covered how StableCover Pro was designed by BDIC from the ground up to align with the needs of sophisticated market participants (mostly institutional and large corporate clients) addressing the convergence of traditional treasury management and blockchain-native digital instruments. Said the second generation Hong Kong resident, 'With this launch, BDIC has further solidified its position as the global leading insurance infrastructure provider for the evolving digital finance landscape.' Kohli continued elaborating, 'The stability BDIC will bring in the normalization for users and platform providers, wallets and exchanges alike,will be additionally executed for corporate treasury management heading into what seems to be a perfect storm for crypto adoption at the institutional level going forward.' BDIC Founder and CEO Jeffrey A. Glusman added, 'StableCover Pro fills a new critical gap in the market based on the interim regulatory guidance.' Who also said when asked about recent US proposed changes and landscape for stablecoins going forward, 'The SEC's recognition of compliant stablecoins as cash equivalents is a watershed moment in financial regulation for the US and the globe. It allows institutions, public and private, to hold digital assets via stablecoins with accounting legitimacy, which is great. However that doesn't eliminate risk. BDIC's goal in delivery of StableCover Pro is to provide the same confidence and operational protection institutions expect when holding fiat or sovereign debt, now applied to digital dollars. This will enhance adoption for corporate balance sheets.' A New Standard for Digital Asset Treasury Protection When asked who the prototypical adopter of the coverage is, Kohli's response was institutional use focus, 'StableCover Pro is purpose-built for Fortune 500 companies, commercial banks, asset managers, pensions, endowments, and insurance firms that are increasingly exploring stablecoins as a functional part of their treasury operations. Family offices will be a no brainer use case to provide extra protection for ultra high net worth wealth'.The PanAsia MD further stated, 'As stablecoins transition from speculative trading tools to bona fide financial infrastructure, risk mitigation becomes essential, not optional, and BDIC will be the insurer leading the crypto space in coverage.' Further details provided by Kohli and the company summary brief on the comprehensive coverage are provided below, as well as plans for product growth and timing of delivery: Core Protection Package includes: Reserve Failure Coverage Protection in the event the stablecoin issuer becomes insolvent or falls below required reserve thresholds, which could jeopardize the coin's 1:1 backing. Redemption Guarantee Safeguards institutional holders during times of stress by covering failed or delayed redemptions beyond an established timeframe. Regulatory Compliance Protection Protects holders from material financial impact if the SEC revokes a stablecoin's cash-equivalent status, including accounting treatment changes and legal expenses. Custody & Technical Risk Coverage Covers losses stemming from smart contract failures, wallet breaches, key mismanagement, or custodian-related issues, including insolvency or operational lapses. Additionally, BDIC plans to offer Premium Add-On Modules to address more nuanced institutional risks which are becoming more and more common, such as: Market Disruption Coverage Protection during periods of extreme volatility or systemic liquidity crunches, particularly those resulting in temporary de-pegs or redemption panics. Cross-Chain Risk Protection Tailored for stablecoins deployed across multiple blockchain environments or bridged onto non-native networks, addressing potential bridge failures and inconsistencies. Why It Matters Now – Timing is Everything for BDIC As the company just announced last week its emerging business BDIC RWA Consulting focusing on tokenization projects and insuring tokens which qualify for the insurers platform, the company vision was further detailed as BDIC leadership recognized the turn of the tide since January in the US. The last six months of US regulatory momentum, which made StableCover Pro an easy add to the offering lineup based on recent progress, and the timing of the RWA division as tokenization momentum continues, are both the result of teamwork at BDIC as equally important developed in response to partner and client requests. Additionally, the company sees the SEC's guidance confirming properly backed stablecoins will be classified as cash equivalents to be a turning point in how digital currency assets are treated on corporate balance sheets going forward and further fuels the token projects in the future. In the BDIC business plan and go to market strategy, this unlocks a new class of enterprise adoption now, when in fact the company thought it was potentially years away. This new revenue driver potential is massive for BDIC, but it also ushers in new fiduciary responsibilities around custody, redemption mechanics, and regulatory status so the company has two aspects to address, the first being the solution for the industry and second internal protocols in compliance and security. BDIC is meeting that moment with StableCover Pro—delivering the solution the offers the protection empowering institutions to engage with digital currency assets confidently, compliantly, and at scale with wallet platforms and exchange affiliate partners at its core for retail user protection, the corporate revenue driver in this space will potentially be a significant revenue increase as adoption rates climb steadily. As the company executes on strategic wallet provider and exchange affiliate partners, it continues to expand its coverage internationally with planned operations in the Caribbean being added to the timeline as well as cooperation with new Sovereign Fund partners around balance sheet assets and debt offerings planned for 2026. Further details on infrastructure partners, industry collaborations and Q4 product delivery were discussed at high levels with focus on security, transparency and consumer needs remaining company priorities as it expands its coverage and product offerings. The company detailed further plans to roll out the C suite executive announcements in addition to several news releases in October leading up to the utility coin offering, including announcing affiliate wallet and exchange partners over the next two months prior to its TGE planned in November as well. Additional details on StableCover Pro can be found here: BDIC About Blockchain Deposit Insurance Corporation Blockchain Deposit Insurance Corporation (BDIC) is the first decentralized cryptocurrency deposit insurer, offering cutting-edge security solutions for digital asset holders. By leveraging blockchain-powered smart contracts and risk assessment algorithms, BDIC provides institutional-grade insurance to safeguard cryptocurrency investments worldwide with offices currently in Central District, Hong Kong and opening locations in additional jurisdictions with Insurance and Foundation Headquarters in PanAsia, Latin America, Europe, Middle East/Africa and the Caribbean. Website: Linkedin: Contact: Blockchain Deposit Insurance Corporation (BDIC)info@ Photo:
Malaysian Reserve
14 hours ago
- Malaysian Reserve
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
WASHINGTON, Aug. 19, 2025 /PRNewswire/ — Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ('Evolent'), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'). Evolent has also granted the initial purchasers in the offering a 30-day option to purchase up to an additional $21.75 million aggregate principal amount of notes. Evolent has increased the size of the offering from $140.0 million to $145.0 million (or $166.75 million if the initial purchasers' option to purchase additional notes is exercised in full). Key terms of the transactions include: Interest on the notes is payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2026, at a rate equal to 4.50% per annum. The notes will mature on August 15, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. The notes are convertible into cash, shares of Evolent's Class A common stock, or a combination of cash and shares of Evolent's Class A common stock, at Evolent's election based on an initial conversion rate of 73.9098 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $13.53 per share of Class A common stock. The initial conversion price represents a premium of approximately 50.0% over the closing price of the Class A common stock on the New York Stock Exchange on August 18, 2025. Evolent has agreed to repurchase 4.43 million shares of its Class A common stock sold short by initial investors in the offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate at a purchase price per share equal to the last reported sale price of Evolent's Class A common stock on August 18, 2025, which was $9.02 per share. John Johnson, Evolent's Chief Financial Officer, stated, 'This transaction helps Evolent avoid over $9 million of annual interest expense when compared to retiring the 2025 notes with our committed incremental credit facilities, while minimizing shareholder dilution with an effective conversion premium over 130% as a result of the concurrent share repurchase, assuming the initial purchasers' option to purchase additional notes is exercised in full. After the retirement of our 2025 notes, Evolent has no maturities until 2029, and we remain committed to our stated capital allocation priority of deploying cash generation to paying down debt.' Subject to satisfaction of certain conditions and subject to Evolent's ability to terminate the conversion rights on or after August 20, 2026 as described below, the notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. On or after August 20, 2026, Evolent may terminate the conversion rights of the notes if (i) for any conversion rights termination date occurring on or after August 20, 2026 and prior to, but not including, August 21, 2028, the last reported sale price of Evolent's Class A common stock has been at least 150% of the conversion price for at least 20 trading days during the 30 consecutive trading day period (including the last trading day of such period) prior to Evolent's delivery of notice of such termination of conversion rights or (ii) for any conversion rights termination date occurring on or after August 21, 2028, the last reported sale price of Evolent's Class A common stock has been at least 130% of the conversion price for at least 20 days during the 30 consecutive trading day period (including the last trading day of such period) prior to Evolent's delivery of notice of such termination of conversion rights. Holders of the notes may require Evolent to repurchase their notes upon the occurrence of a 'fundamental change' (as defined in the indenture that will govern the notes) at a price equal to 100% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest. Evolent may not redeem the notes unless and until holders' conversion rights have been terminated at its election. However, if holders' conversion rights have been terminated, Evolent may redeem for cash all or a portion of the notes at a redemption price equal to 100% of the principal amount of the notes being redeemed, plus any accrued and unpaid interest. Evolent estimates that the net proceeds from the offering will be approximately $140.2 million (or approximately $161.2 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting fees and estimated expenses payable by Evolent. Evolent expects to use approximately $100.2 million of the net proceeds from the offering, plus available liquidity, to repurchase approximately $167.4 million aggregate principal of its 1.50% convertible senior notes due 2025 (the '2025 Notes') for approximately $167.6 million in cash in note repurchases entered into concurrently with the pricing of the notes. Evolent also expects to use approximately $40.0 million of the net proceeds from the offering to repurchase shares of Evolent's Class A common stock concurrently with the pricing of the offering in privately negotiated transactions. If the initial purchasers exercise their option to purchase additional notes, Evolent expects to use the net proceeds from the sale of the additional notes to reduce the amount of available liquidity required to repurchase or repay the 2025 Notes. In connection with the concurrent share repurchase described above, Evolent has agreed to repurchase shares of its Class A common stock sold short by initial investors in the offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate at a purchase price per share equal to the last reported sale price of Evolent's Class A common stock on August 18, 2025, which was $9.02 per share. These repurchases could increase (or reduce the size of any decrease in) the market price of Evolent's Class A common stock or the notes. In the case of repurchases effected concurrently with the offering, this activity could affect the market price of Evolent's Class A common stock prior to, concurrently with or shortly after the pricing of the notes, and could result in a higher effective conversion price for the notes. In connection with the repurchases of the 2025 Notes described above, Evolent expects that holders of the 2025 Notes who agree to have their 2025 Notes repurchased and who have hedged their equity price risk with respect to such 2025 Notes will unwind all or part of their hedge positions by buying Evolent's Class A common stock and/or entering into or unwinding various derivative transactions with respect to Evolent's Class A common stock. This activity could increase (or reduce the size of any decrease in) the market price of Evolent's Class A common stock, including concurrently with or shortly after the pricing of the notes, resulting in a higher effective conversion price of the notes. Evolent cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or Evolent's Class A common stock and the corresponding effect on the initial conversion price of the notes. Consummation of the sale of the notes is subject to customary closing conditions, and there can be no assurance that the offering of the notes will be consummated. Settlement is expected to occur on August 21, 2025. The notes and any shares of Class A common stock of Evolent issuable upon conversion of the notes will not be registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such jurisdiction. About Evolent Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Contact: investorrelations@ Forward-Looking Statements – Cautionary Language Certain statements made in this press release are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA'). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: 'believe,' 'anticipate,' 'expect,' 'estimate,' 'aim,' 'predict,' 'potential,' 'continue,' 'plan,' 'project,' 'will,' 'should,' 'shall,' 'may,' 'might' and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, trends in our businesses, prospective services, future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. The company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These risks and uncertainties are discussed under the headings 'Forward-Looking Statements – Cautionary Language,' and 'Risk Factors,' in the company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission (the 'SEC'), and in the company's other filings with the SEC, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, the company does not have any intention or obligation to publicly update or revise any forward-looking statements after issuing this release, whether to reflect any future events or circumstances or otherwise.
